Criblage inhibiteurs usp8

A method of treating an adrenocorticotropin hormone (ACTH)-dependent Cushing's syndrome, wherein said ACTH-dependent Cushing's syndrome is a Cushing's disease, the method comprising:

• administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a patient in need thereof:
• wherein
• R1 is H or a —C(O)—R9, wherein R9 is a C1-C3 linear or branched, saturated or unsaturated, alkyl group,
• R2 is H or a halogen,
• R3 is a halogen,
• R4 and R8 are, independently, H or a halogen,
• R5 is H, a C1-C3, linear or branched, saturated or unsaturated, alkyl group, OH, or a halogen,
• R6 is H, a halogen, or —C(O)—Ar, wherein Ar is a C6-C10 aryl group, Ar being optionally substituted with a C1-C3 linear or branched, saturated or unsaturated, alkyl group,
• R7 is H, a halogen, a C1-C3, linear or branched, saturated or unsaturated, alkyl group, —NO2, or —B—Ar, wherein B is O or —C(CN)—, and Ar is a C6-C10 aryl group, Ar being optionally substituted with a halogen, and
• wherein if R2 is H, then at least one of R5, R6, R7 and R8 is not H.